Pharmaceutical GMP Readiness in South Korea
South Korea's Ministry of Food and Drug Safety (MFDS, formerly KFDA) regulates medicines under the Pharmaceutical Affairs Act and the Regulation on Safety of Medicinal Products.
In Short
- MFDS is the competent authority; provincial offices conduct routine inspections.
- Domestic manufacturers and importers require MFDS licensing.
- Submissions and labelling are in Korean; technical supporting data in English is widely accepted.
Korean GMP (KGMP) is aligned with PIC/S — MFDS became a PIC/S member in 2014 — and converges with EudraLex Vol 4. Marketing requires an authorized importer/manufacturer in Korea. Serialization of prescription drugs is mandatory through the Korea Pharmaceutical Information Service (KPIS). This guide covers the Korea-specific layer over an ICH Q10 PQS.
Regulator and Legal Basis
MFDS is the competent authority; provincial offices conduct routine inspections. Pharmaceutical Affairs Act is the statutory base; the KGMP regulation aligns with PIC/S PE 009.
More on regulator and Legal Basis
Korea is ICH and PIC/S; MFDS publishes notices in Korean with English summaries.
Licensing, Release, and Serialization
Domestic manufacturers and importers require MFDS licensing. Release is by an authorized person under the QMS — no statutory QP.
More on licensing, Release, and Serialization
Serialization at saleable-unit level is mandatory for prescription drugs through KPIS, using a national identifier alongside GS1; aggregation reporting is required for supply-chain events.
Documentation and Language
Submissions and labelling are in Korean; technical supporting data in English is widely accepted. SOPs at foreign sites do not need to be Korean but key inspection records are often translated for MFDS inspectors.
Inspection Style and Common Findings
MFDS inspections follow PIC/S structure with critical/major/other classifications. Common findings: data integrity, Annex 1 contamination control, validation lifecycle, and supplier qualification.
More on inspection Style and Common Findings
MFDS is increasingly aligned with PIC/S peers and routinely shares inspection intelligence.
A 90–180 day South Korea readiness path
- Days 0–30
identify Korean MAH/importer; map products and confirm KPIS onboarding.
- Days 31–90
align KGMP documentation; prepare Korean labelling.
- Days 91–180
pre-inspection readiness with PIC/S-style evidence packs; host MFDS inspection.
Questions
Is Korea a PIC/S member?
Yes since 2014. MFDS GMP inspections are recognized by other PIC/S members and vice versa, with reliance applied on a case-by-case basis.
How does KPIS differ from EU FMD?
Both serialize at saleable-unit level and require event reporting. KPIS uses a national identifier scheme reported to the KPIS hub; EU FMD uses a unique identifier verified at dispense via EMVS. Aggregation requirements in Korea are stricter.
Do we need a Korean QP?
No — the licensed manufacturer or importer appoints a quality manager responsible for release. The role is required by KGMP but is not a statutory QP equivalent to the EU model.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
- Who decides, and who may not
- Supplier to finished bulk
- Test, review, investigate
- Packs, serialisation and recall
Plus Evidence map and four worksheets.
Get the pharmaceutical guideWe ask for your name and email so we can handle this request. The full guide then opens on this site, ready to translate, print or save. Privacy policy. Practical orientation, not legal advice; your quality unit decides which rules apply.
UltimateFree guide
The Pharmaceutical Operations Guide
Right material. Right record. Released by a person.
Keep reading
Global Pharmaceutical GMP Readiness: Principles That Travel- Australia Pharmaceutical GMP Readiness: TGA and PIC/S GMP
Brazil Pharmaceutical GMP Readiness: ANVISA RDC 658/2022
Canada Drug GMP Readiness: Food and Drug Regulations Part C, Division 2
China Pharmaceutical GMP Readiness: NMPA and China GMP
EU GMP Guide: EudraLex Volume 4 Chapters, Annexes and Who Decides